Home » Market News » DirectorsTalk Highlights » EpiSwitch technology
Oxford BioDynamics

EpiSwitch technology

EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework from which changes in the regulation of a genome can be analysed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities.

Chromosomal Conformation Capture

The packaging of chromosomal DNA plays a critical role in the epigenetic regulation of the whole genome. It ensures effective storage, access to genetic information and its regulation by the complex protein machinery utilised in gene expression. 

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.